Clinical Feature Analysis for Respiratory Disease and/or Hypoxia Related Pulmonary Hypertension in 31 Patients
10.3969/j.issn.1000-3614.2018.01.013
- VernacularTitle:31例呼吸疾病和(或)缺氧合并肺动脉高压患者的临床特征分析
- Author:
Liu GAO
1
;
Zhi-Hong LIU
;
Zhi-Hui ZHAO
;
Qin LUO
;
Qing ZHAO
;
Xiu-Ping MA
;
Hong-Liang ZHANG
;
Yong WANG
;
Zhi-Wei HUANG
;
Yi TANG
;
Xue YU
;
Qi JIN
Author Information
1. 北京协和医学院 中国医学科学院 国家心血管病中心 阜外医院 肺血管病诊治中心
- Keywords:
Hypertension,pulmonary;
Hypoxia;
Sleep apnea-hypopnea syndrome
- From:
Chinese Circulation Journal
2018;33(1):69-72
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinical features in patients with respiratory disease and/or hypoxia related severe pulmonary hypertension. Methods: Our research included in 2 groups: Hypoxia related pulmonary hypertension group, the patients with respiratory disease and/or hypoxia combining severe pulmonary hypertension, n=31 and Severe idiopathic pulmonary hypertension group, n=41. The diagnosis was confirmed by right heart catheterization; the patients treated in our hospital from 2016-01 to 2017-01 were consecutively enrolled and studied. Clinical features and treatment were compared between 2 groups. Results: Compared with Severe idiopathic pulmonary hypertension group, the patients' mean age, BMI and blood pressure were higher in Hypoxia related pulmonary hypertension group, while the majority clinical features were similar between 2 groups. In Hypoxia related pulmonary hypertension group, more patients had obstructive sleep apnea-hypopnea syndrome (OSAHS) with the higher AHI and the lower mean blood oxygen pressure at night, increased diameters of left atria and ventricle, elevated NT-proBNP level and reduced 6 minutes walking distance; some patients tried target drug therapy, calcium channel blocker therapy or continuous positive airway pressure therapy. Conclusion: Respiratory disease especially OSAHS should be screened from the patients with severe pulmonary hypertension. In addition to basic respiratory and hypoxia medication, further investigation is needed to confirm whether the prognosis could be improved by calcium channel blocker therapy and target drug therapy.
